

1 Supplementary Methods

2

3 PCR genotyping of mice

4 hOX40 KI was detected using the following primers F –

5 AGTGCCCACGCTTCCTGAGGA and R - CTTGAGGATGCCAGAGGAGGC

6 which give a 290bp product. mOX40 was detected using the following primers

7 F -TCTCCACCCACCTTGGTGACT and R – GCCAGCAGGACAGTCAAGGA

8 which give a 174bp product.

9

10 Antibody Production and labelling

11 Anti-hOX40 mAb were created using conventional hybridoma technology [49].

12 Isotype switching was carried out as previously described [50] and mAb

13 purified either using a protein-G or a protein-A column. All preparations were

14 deemed endotoxin low (<1 ng/mg protein). Anti-hOX40 mAb were FITC

15 (Sigma) labelled at a ratio of 1:10 FITC:mAb and purified using a desalting

16 column (GE Healthcare).

17

18 Surface Plasmon Resonance

19 A Biacore T100 upgraded to a T200 (GE Life Sciences) was used to measure

20 interactions with hOX40. For affinity determination 1 µg/ml of hOX40-hFc was

21 immobilised onto a CM5 chip (GE Healthcare) and a range of concentrations

22 (0-500nM) of anti-hOX40 mAb was injected over the chip. For ligand binding

23 to hOX40; 1 µg/ml of hOX40-hFc was immobilised onto a CM5 chip coated

24 with an anti-Fc antibody and hOX40L, mOX40L, h4-1BBL or m4-1BBL

25 (15 µg/ml) was injected over the chip.

26

27 *In vitro* assays

28 hPBMC proliferation assays: hPBMCs were isolated using lymphoprep

29 separation. For proliferation assays cells were labelled with 1 µM CFSE

30 immediately following isolation, cultured at high density (1.5×10^7 cells/ml) for 2

31 days at 37°C, then plated at 1×10^5 cells/well. Cells were stimulated with

32 soluble anti-CD3 (OKT3, 5ng/ml) and anti-hOX40 mAb (5 µg/ml). Cells were

33 stained with appropriate antibodies and CFSE dilution assessed via flow
34 cytometry.

35 Murine expression assays; splenocytes were isolated using a 100µm strainer
36 and red cell lysed using ACK lysis buffer. Cells were plated at 2×10^5 cells/well
37 and stimulated with soluble anti-CD3 (145-2C11, 0.1µg/ml) and anti-CD28
38 (37.51, 1µg/ml). Cells were stained with appropriate antibodies and analysed
39 by flow cytometry.

40 Murine proliferation assays; splenocytes were isolated using a 100µm strainer
41 and red cell lysed using ACK lysis buffer. Cells were labelled with 5µM CFSE,
42 plated at 1×10^5 cells/well and stimulated with platebound anti-CD3 (145-2C11,
43 1µg/ml) and anti-OX40 mAb (10µg/ml). Cells were incubated for 72 hours,
44 stained with appropriate antibodies and analysed for CFSE dilution by flow
45 cytometry.

46

47

48 Flow cytometry

49 Flow cytometry antibodies are listed in Supplementary Table 1. Intracellular
50 staining was performed using Foxp3 staining buffer kit (ThermoFisher-
51 eBioscience) according to the manufacturer's protocol. Cells from ovarian
52 cancer patients were incubated with 10mg/ml KIOVIG (Baxalta) prior to
53 staining with relevant antibodies. All flow cytometry experiments were
54 performed using either a FACSCalibur, FACSCanto, FACS Aria or FACSVerse
55 machine (all BD Bioscience). Data analysed using Cellquest Pro, FACSDiva
56 (V6.1.2), FlowJo (all BD Bioscience) or FCS Express (V.3) software (De Novo
57 Software).

58

59